(2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200.
(2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep, 7, 2059-2070. http://doi.org/10.1016/j.ekir.2022.05.033.
(2022). Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study). Bmj Open, 12, e060413. http://doi.org/10.1136/bmjopen-2021-060413.
(2006). Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther. http://doi.org/10.1016/j.clinthera.2006.03.005.
(2011). Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?. Diabetes Obes Metab. http://doi.org/10.1111/j.1463-1326.2011.01413.x.